MCID: FRN030
MIFTS: 22

Frontotemporal Dementia with Parkinsonism-17

Categories: Mental diseases, Genetic diseases

Aliases & Classifications for Frontotemporal Dementia with Parkinsonism-17

MalaCards integrated aliases for Frontotemporal Dementia with Parkinsonism-17:

Name: Frontotemporal Dementia with Parkinsonism-17 24 69
Disinhibition-Dementia-Parkinsonism-Amytrophy Complex 24
Wilhelmsen-Lynch Disease 24
Frontotemporal Dementia 69
Familial Pick's Disease 24
Ftdp-17 24
Ddpac 24

Classifications:



External Ids:

Summaries for Frontotemporal Dementia with Parkinsonism-17

Genetics Home Reference : 24 Frontotemporal dementia with parkinsonism-17 (FTDP-17) is a brain disorder. It is part of a group of conditions, called frontotemporal dementia or frontotemporal degeneration, that are characterized by a loss of nerve cells (neurons) in areas of the brain called the frontal and temporal lobes. Over time, a loss of these cells can affect personality, behavior, language, and movement.

MalaCards based summary : Frontotemporal Dementia with Parkinsonism-17, also known as disinhibition-dementia-parkinsonism-amytrophy complex, is related to frontotemporal dementia and grn-related frontotemporal dementia, and has symptoms including personality changes The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and testes.

Related Diseases for Frontotemporal Dementia with Parkinsonism-17

Diseases related to Frontotemporal Dementia with Parkinsonism-17 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 frontotemporal dementia 11.3
2 grn-related frontotemporal dementia 10.9
3 dementia 10.4

Symptoms & Phenotypes for Frontotemporal Dementia with Parkinsonism-17

UMLS symptoms related to Frontotemporal Dementia with Parkinsonism-17:


personality changes

Drugs & Therapeutics for Frontotemporal Dementia with Parkinsonism-17

Drugs for Frontotemporal Dementia with Parkinsonism-17 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
3
Citalopram Approved Phase 4 59729-33-8 2771
4
Iodine Approved, Investigational Phase 4 7553-56-2 807
5
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
6 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1
7
Serotonin Phase 4,Phase 3 50-67-9 5202
8 Serotonin Agents Phase 4,Phase 3
9 Serotonin Uptake Inhibitors Phase 4
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
11 Neurotransmitter Uptake Inhibitors Phase 4
12 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
14 Antidepressive Agents Phase 4,Phase 2,Phase 1
15 Antidepressive Agents, Second-Generation Phase 4
16 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
17 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
18 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
19 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
20 Antiparkinson Agents Phase 4,Phase 3,Phase 2
21 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Analgesics Phase 4,Phase 1
23 Analgesics, Non-Narcotic Phase 4,Phase 1
24 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
25 Anti-Inflammatory Agents Phase 4,Phase 1
26 cadexomer iodine Phase 4
27 Calamus Nutraceutical Phase 4
28
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
29
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
30
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
31
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
32
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
33
Methylene blue Approved, Investigational Phase 3 61-73-4
34
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
35
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
36
Iron Approved Phase 2, Phase 3 7439-89-6 23925
37
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
38 tannic acid Approved, Nutraceutical Phase 3
39
1-Deoxynojirimycin Experimental Phase 3,Phase 2 19130-96-2 1374
40 Prednisolone acetate Phase 2, Phase 3
41 Alkylating Agents Phase 2, Phase 3
42 Methylprednisolone acetate Phase 2, Phase 3
43 Methylprednisolone Hemisuccinate Phase 2, Phase 3
44 Glycoside Hydrolase Inhibitors Phase 3,Phase 2,Phase 1
45 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
46 Anti-HIV Agents Phase 3,Phase 2,Phase 1
47 Antilymphocyte Serum Phase 2, Phase 3
48 Prednisolone hemisuccinate Phase 2, Phase 3
49 Immunosuppressive Agents Phase 2, Phase 3
50 Prednisolone phosphate Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 150)

# Name Status NCT ID Phase Drugs
1 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
2 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
3 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
4 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
5 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
6 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
7 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
8 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
9 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
10 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
11 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
12 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
13 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
14 SurVival of Lysosomal Acid Lipase Deficiency (LAL-D) Infants Treated With SebelipAse aLfa Active, not recruiting NCT01371825 Phase 2, Phase 3 Sebelipase alfa (SBC-102)
15 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Enrolling by invitation NCT02245568 Phase 3 TRx0237
16 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Not yet recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet
17 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
18 Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102 Terminated NCT01473875 Phase 2, Phase 3 SBC-102
19 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
20 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
21 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
22 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
23 Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
24 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
25 Electroencephalography (EEG) Biofeedback Training to Improve Executive Functioning and Memory in Adults With a Dementing Illness Completed NCT01168466 Phase 2
26 Double Blind Trial of DC Polarization in FTD Completed NCT00117858 Phase 2
27 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
28 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
29 Intranasal Oxytocin for Frontotemporal Dementia Recruiting NCT03260920 Phase 2 Syntocinon
30 Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia Recruiting NCT02862210 Phase 2 Lithium Carbonate;Placebo
31 Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Recruiting NCT01937013 Phase 2 Intranasal oxytocin;Saline Nasal Mist
32 Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
33 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
34 F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis Recruiting NCT02414230 Phase 2 Drug: F 18 T807
35 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
36 Effects of Tolcapone on Frontotemporal Dementia Active, not recruiting NCT00604591 Phase 2 Tolcapone;Placebo
37 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Active, not recruiting NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray
38 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
39 Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency Active, not recruiting NCT02193867 Phase 2 sebelipase alfa
40 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Enrolling by invitation NCT02676843 Phase 2 18F-AV-1451
41 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
42 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
43 F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) Withdrawn NCT02707978 Phase 2 F 18 T807
44 Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia Unknown status NCT00674960 Phase 1
45 Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment Unknown status NCT00149175 Phase 1
46 Far Infrared Radiation Treatment of Dementia and Other Mental Illness Unknown status NCT00574054 Phase 1
47 Safety Study of Intranasal Oxytocin in Frontotemporal Dementia Completed NCT01386333 Phase 1 oxytocin;Saline Nasal Mist
48 Direct Current Brain Polarization in Frontotemporal Dementia Completed NCT00077896 Phase 1
49 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270
50 Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease Completed NCT00316498 Phase 1 OGT918

Search NIH Clinical Center for Frontotemporal Dementia with Parkinsonism-17

Genetic Tests for Frontotemporal Dementia with Parkinsonism-17

Anatomical Context for Frontotemporal Dementia with Parkinsonism-17

MalaCards organs/tissues related to Frontotemporal Dementia with Parkinsonism-17:

38
Brain, Temporal Lobe, Testes, Prefrontal Cortex, Cortex, Bone, Eye

Publications for Frontotemporal Dementia with Parkinsonism-17

Articles related to Frontotemporal Dementia with Parkinsonism-17:

# Title Authors Year
1
Familial Pick's disease and dementia in frontal lobe degeneration of non-Alzheimer type are not variants of prion disease. ( 8006666 )
1994

Variations for Frontotemporal Dementia with Parkinsonism-17

Expression for Frontotemporal Dementia with Parkinsonism-17

Search GEO for disease gene expression data for Frontotemporal Dementia with Parkinsonism-17.

Pathways for Frontotemporal Dementia with Parkinsonism-17

GO Terms for Frontotemporal Dementia with Parkinsonism-17

Sources for Frontotemporal Dementia with Parkinsonism-17

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....